Quality of life and efficacy of temozolomide combined with whole-brain radiotherapy in patients with brain metastases from non-small-cell lung cancer

Lv,Yajuan; Zhang,Jiandong; Liu,Zhen; Liang,Ning; Tian,Yuan

doi:10.3892/mco.2018.1622

Quality of life and efficacy of temozolomide combined with whole-brain radiotherapy in patients with brain metastases from non-small-cell lung cancer

Authors:
- Yajuan Lv
- Jiandong Zhang
- Zhen Liu
- Ning Liang
- Yuan Tian
View Affiliations

Affiliations: Department of Radiology, Shandong Provincial Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong 250014, P.R. China
Published online on: May 10, 2018 https://doi.org/10.3892/mco.2018.1622
Pages: 70-74

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the efficacy and life quality of temozolomide (TMZ) combined with whole-brain radiotherapy (WBRT) for patients with brain metastases (BM) from non-small-cell lung cancer (NSCLC). A total of 77 cases of patients with lung cancer and BM were selected and divided into two groups; the first group was administered WBRT with TMZ, and the second group was administered WBRT with placebo. The efficacy, overall survival (OS) and quality of life (QoL) were then compared between the two groups. There were no significant differences in toxicity between the two groups. However, the first group exhibited an advantage over the second group in terms of objective response and OS (P<0.5). Therefore, WBRT may improve the QoL of patients with BM. TMZ concomitantly with WBRT was well-tolerated and may be recommended for the treatment of BM from NSCLC.

View Figures

View References

1	Seoane J and De Mattos-Arruda L: Brain metastasis: New opportunities to tackle therapeutic resistance. Mol Oncol. 8:1120–1131. 2014. View Article : Google Scholar : PubMed/NCBI
2	Berger LA, Riesenberg H, Bokemeyer C and Atanackovic D: CNS metastases in non-small-cell lung cancer: Current role of EGFR-TKI therapy and future perspectives. Lung Cancer. 80:242–248. 2013. View Article : Google Scholar : PubMed/NCBI
3	Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, et al: Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 30:419–425. 2012. View Article : Google Scholar : PubMed/NCBI
4	Tabouret E, Chinot O, Metellus P, Tallet A, Viens P and Gonçalves A: Recent trends in epidemiology of brain metastases: An overview. Anticancer Res. 32:4655–4662. 2012.PubMed/NCBI
5	Baykara M, Kurt G, Buyukberber S, Demirci U, Ceviker N, Algin E, Coskun U, Aykol S, Emmez H, Ozet A, et al: Management of brain metastases from non-small cell lung cancer. J Cancer Res Ther. 10:915–921. 2014. View Article : Google Scholar : PubMed/NCBI
6	Scoccianti S and Ricardi U: Treatment of brain metastases: Review of phase III randomized controlled trials. Radiother Oncol. 102:168–179. 2012. View Article : Google Scholar : PubMed/NCBI
7	Walbert T and Gilbert MR: The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol. 14:299–306. 2009. View Article : Google Scholar : PubMed/NCBI
8	Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, Komaki R, Souhami L, Buyyounouski MK, Khuntia D, Demas W, et al: A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys. 85:1312–1318. 2013. View Article : Google Scholar : PubMed/NCBI
9	Chun SG, Choe KS, Iyengar P, Yordy JS and Timmerman RD: Isolated central nervous system progression on Crizotinib: An Achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biol Ther. 13:1376–1383. 2012. View Article : Google Scholar : PubMed/NCBI
10	Tatar Z, Thivat E, Planchat E, Gimbergues P, Gadea E, Abrial C and Durando X: Temozolomide and unusual indications: Review of literature. Cancer Treat Rev. 39:125–135. 2013. View Article : Google Scholar : PubMed/NCBI
11	Chua D, Krzakowski M, Chouaid C, Pallotta MG, Martinez JI, Gottfried M, Curran W and Throuvalas N: Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: A randomized, open-label phase II study. Clin Lung Cancer. 11:176–181. 2010. View Article : Google Scholar : PubMed/NCBI
12	Gamboa-Vignolle C, Ferrari-Carballo T, Arrieta Ó and Mohar A: Whole-brain irradiation with concomitant daily fixed-dose temozolomide for brain metastases treatment: A randomised phase II trial. Radiother Oncol. 102:187–191. 2012. View Article : Google Scholar : PubMed/NCBI
13	Christodoulou C, Bafaloukos D, Linardou H, Aravantinos G, Bamias A, Carina M, Klouvas G and Skarlos D: Hellenic Cooperative Oncology Group: Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: A Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol. 71:61–65. 2005. View Article : Google Scholar : PubMed/NCBI
14	Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R and Coleman CN: CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
15	Ferrarese F, Baggio V, Zorat PL and Fiore D: Treatment and prophylaxis for brain metastases from non-small cell lung cancer: whole brain radiation treatment versus stereotactic radiosurgery. Ann Oncol Suppl. 2:ii71–ii72. 2006. View Article : Google Scholar
16	Larson D and Sahgal A, Larson D and Sahgal A: Adjuvant whole brain radiotherapy: strong emotions decide but rationale studies are needed: in regard to Brown et al. (Int J Radiat Oncol Biol Phys 2008;70:1305-1309). In reply to Drs. Larson and Sahgal. Int J Radiat Oncol Biol Phys. 75:316–317. 2009.
17	Liu R, Wang X, Ma B, Yang K, Zhang Q and Tian J: Concomitant or adjuvant temozolomide with whole-brain irradiation for brain metastases: A meta-analysis. Anticancer Drugs. 21:120–128. 2010. View Article : Google Scholar : PubMed/NCBI
18	Zhao Q, Qin Q, Sun J, Han D, Wang Z, Teng J and Li B: Brain radiotherapy plus concurrent temolomide versus radiotherapy alone for patients with brain metastases: A meta-analysis. PLoS One. 11:e01504192016. View Article : Google Scholar : PubMed/NCBI
19	Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P and Throuvalas N: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 20:3644–3650. 2002. View Article : Google Scholar : PubMed/NCBI
20	Xia Deng, Zhen Zheng, Baochai Lin, et al: The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases. BMC cancer. 17:422017. View Article : Google Scholar : PubMed/NCBI
21	Addeo R, Caraglia M, Faiola V, Capasso E, Vincenzi B, Montella L, Guarrasi R, Caserta L and Del Prete S: Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life. BMC Cancer. 7:182007. View Article : Google Scholar : PubMed/NCBI
22	Ma W, Li N, An Y, Zhou C, Bo C and Zhang G: Effects of Temozolomide and Radiotherapy on Brain Metastatic Tumor: A Systematic Review and Meta-Analysis. World Neurosurg. 92:197–205. 2016. View Article : Google Scholar : PubMed/NCBI
23	Qin H, Pan F, Li J, Zhang X, Liang H and Ruan Z: Whole brain radiotherapy plus concurrent chemotherapy in non-small cell lung cancer patients with brain metastases: A meta-analysis. PLoS One. 9:e1114752014. View Article : Google Scholar : PubMed/NCBI
24	Hassler MR, Pfeifer W, Knocke-Abulesz TH, Geissler K, Altorjai G, Dieckmann K and Marosi C: Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: A multicentric Austrian phase II study. Wien Klin Wochenschr. 125:481–486. 2013. View Article : Google Scholar : PubMed/NCBI
25	Zheng MH, Sun HT, Xu JG, Yang G, Huo LM, Zhang P, Tian JH and Yang KH: Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis. BioMed Res Int. 2016:58073462016. View Article : Google Scholar : PubMed/NCBI
26	Broniscer A, Panetta JC, O'Shaughnessy M, Fraga C, Bai F, Krasin MJ, Gajjar A and Stewart CF: Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res. 13:1511–1515. 2007. View Article : Google Scholar : PubMed/NCBI
27	Chow R, Lao N, Popovic M, Chow E, Cella D, Beaumont J, Lam H, Pulenzas N, Bedard G, Wong E, et al: Comparison of the EORTC QLQ-BN20 and the FACT-Br quality of life questionnaires for patients with primary brain cancers: A literature review. Support Care Cancer. 22:2593–2598. 2014. View Article : Google Scholar : PubMed/NCBI
28	Pulenzas N, Ray S, Zhang L, McDonald R, Cella D, Rowbottom L, Sahgal A, Soliman H, Tsao M, Danjoux C, et al: The Brain Symptom and Impact Questionnaire in brain metastases patients: A prospective long-term follow-up study. CNS Oncol. 5:31–40. 2016. View Article : Google Scholar : PubMed/NCBI
29	Pan CJ, Liu HC, Liang SY, Liu CY, Wu WW and Cheng SF: Resilience and coping strategies influencing the quality of life in patients with brain tumor. Clin Nurs Res Jun. 1:10547738177145622017.